Eli Gilboa
Immunology · 2005–2007
A researcher in the Science corpus: 3 papers; trusts 4 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Immunology — 25 citations into it
Whom Eli Gilboa trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from Eli Gilboa's perspective
Ordered by how strongly the researchers Eli Gilboa trusts endorse each paper. Same corpus, a different order for every researcher.
- Activation of the interferon system by short-interfering RNAs (Nature Cell Biology)
- Characterization of Dicer-deficient murine embryonic stem cells. (Proceedings of the National Academy of Sciences of the United States of America)
- Aptamers: an emerging class of therapeutics. (Annual Review of Medicine)
- Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy (Nature Biotechnology)
- Toll-like receptor signalling (Nature reviews. Immunology)
- Foxp3 programs the development and function of CD4+CD25+ regulatory T cells (Nature Immunology)
- Differential Antigen Processing by Dendritic Cell Subsets in Vivo (Science)
- Plasmacytoid dendritic cells in immunity (Nature Immunology)
- Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells (Nature)
- IL-17 family cytokines and the expanding diversity of effector T cell lineages. (Annual Review of Immunology)
Their papers
- Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras (2006) — 991 citations
- DC-based cancer vaccines. (2007) — 598 citations
- Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. (2005) — 1,029 citations